Essential Reads: Duloxetine and Pregnancy (2021)
In this large study with over 1500 exposures, duloxetine exposure during the first trimester does not appear to increase risk of major malformations.
Impact of Antidepressants on Male Fertility: New Data on Duloxetine
The current study indicates that duloxetine administered at a dose of 60 mg does not have an impact on sperm quality.
Clinical Update 2020: New Data on Duloxetine and Pregnancy
A few weeks ago, we published a clinical update for duloxetine (Cymbalta) and pregnancy, stating that there was little new to report since we last covered the topic in 2015. It is somewhat amusing [...]
Clinical Update 2020: Duloxetine and Pregnancy
Women face difficult choices when deciding whether or not to continue psychiatric medications during pregnancy. For many years, we have typically recommended the older antidepressants, including the selective serotonin reuptake inhibitors or SSRIs such [...]
Venlafaxine and Duloxetine: Pooled Analysis Shows No Increase in Risk of Malformations
Women face difficult choices when deciding whether or not to continue psychiatric medications during pregnancy. This choice can be especially difficult for women taking newer medications which lack adequate reproductive safety data. While we have [...]
You Asked: Is Duloxetine (Cymbalta) Safe To Use During Pregnancy?
You can find a more recent post on this topic here: Venlafaxine and Duloxetine: Pooled Analysis Shows No Increase in Risk of Malformations We receive a fair number of questions on the use of duloxetine [...]
Research from the CWMH: Duloxetine for Menopausal Symptoms
A substantial proportion of women transitioning into menopause experience a new onset or recurrence of depressive symptoms. A new study from the Center for Women’s Mental Health indicates that duloxetine (Cymbalta) is effective for the treatment of depression and may also have a beneficial effect on vasomotor symptoms (hot flashes and night sweats).
Duloxetine and Pregnancy: Preliminary Data
Duloxetine (sold in the United Sates under the brand name of Cymbalta) is a serotonin-norepinephrine reuptake inhibitor (SNRI) effective for major depressive disorder and generalized anxiety disorder (GAD). Although used fairly commonly in women of child-bearing age, information regarding its reproductive safety has been lacking.
Making Individual Decisions Regarding the Use of Antidepressants During Pregnancy
Women face difficult choices when deciding whether or not to continue psychiatric medications during pregnancy. This choice can be especially difficult for women taking newer medications which lack adequate reproductive safety data.
Duloxetine for the Treatment of Menopausal Symptoms and Mood in Postmenopausal Women
Depression is common in postmenopausal women suffering from menopausal vasomotor symptoms (hot flushes, night sweats) and insomnia. While estrogen replacement therapy may alleviate these symptoms and may also have a positive impact on mood, the use of estrogen has declined over recent years. There has been great interest in finding alternative strategies for the management of menopausal symptoms, and recent data suggest that selective serotonin reuptake inhibitor antidepressants (SSRIs) and the serotonin norepinephrine reuptake inhibitor (SNRI), venlafaxine, may be effective for the treatment of depression and vasomotor symptoms in peri- and postmenopausal women. In a study presented at the annual meeting of the American Psychiatric Association, Dr. Hadine Joffe and her colleagues at the Center of Women’s Mental Health presented data on the use of duloxetine (Cymbalta), a new SNRI, for the treatment of mood, vasomotor symptoms, and insomnia in postmenopausal women.